Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF(V600)-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

PURPOSE: Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors. This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Johnson, Douglas B., Flaherty, Keith T., Weber, Jeffrey S., Infante, Jeffrey R., Kim, Kevin B., Kefford, Richard F., Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Sharfman, William H., McWilliams, Robert R., Sznol, Mario, Lawrence, Donald P., Gibney, Geoffrey T., Burris, Howard A., Falchook, Gerald S., Algazi, Alain, Lewis, Karl, Long, Georgina V., Patel, Kiran, Ibrahim, Nageatte, Sun, Peng, Little, Shonda, Cunningham, Elizabeth, Sosman, Jeffrey A., Daud, Adil, Gonzalez, Rene
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2014
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226803/
https://ncbi.nlm.nih.gov/pubmed/25287827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.3535
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki